BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 33204322)

  • 21. Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy.
    Li J; Chen L; Xiong Y; Zheng X; Xie Q; Zhou Q; Shi L; Wu C; Jiang J; Wang H
    Cell Physiol Biochem; 2017; 41(3):907-920. PubMed ID: 28222426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tristetraprolin Overexpression in Gastric Cancer Cells Suppresses PD-L1 Expression and Inhibits Tumor Progression by Enhancing Antitumor Immunity.
    Guo J; Qu H; Shan T; Chen Y; Chen Y; Xia J
    Mol Cells; 2018 Jul; 41(7):653-664. PubMed ID: 29936792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer.
    Zeng Z; Yang B; Liao Z
    Future Oncol; 2021 Apr; 17(12):1553-1569. PubMed ID: 33397136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Verteporfin targeting YAP1/TAZ-TEAD transcriptional activity inhibits the tumorigenic properties of gastric cancer stem cells.
    Giraud J; Molina-Castro S; Seeneevassen L; Sifré E; Izotte J; Tiffon C; Staedel C; Boeuf H; Fernandez S; Barthelemy P; Megraud F; Lehours P; Dubus P; Varon C
    Int J Cancer; 2020 Apr; 146(8):2255-2267. PubMed ID: 31489619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proteogenomic analysis of NCC-S1M, a gastric cancer stem cell-like cell line that responds to anti-PD-1.
    Park JW; Um H; Yang H; Ko W; Kim DY; Kim HK
    Biochem Biophys Res Commun; 2017 Mar; 484(3):631-635. PubMed ID: 28153736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. LGR5 Is a Gastric Cancer Stem Cell Marker Associated with Stemness and the EMT Signature Genes NANOG, NANOGP8, PRRX1, TWIST1, and BMI1.
    Wang B; Chen Q; Cao Y; Ma X; Yin C; Jia Y; Zang A; Fan W
    PLoS One; 2016; 11(12):e0168904. PubMed ID: 28033430
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
    Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
    J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed death ligand 1 regulates epithelial-mesenchymal transition and cancer stem cell phenotypes in hepatocellular carcinoma through the serum and glucocorticoid kinase 2/β-catenin signaling pathway.
    Kong X; Peng H; Liu P; Fu X; Wang N; Zhang D
    Cancer Sci; 2023 Jun; 114(6):2265-2276. PubMed ID: 36751987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. APE1 facilitates PD-L1-mediated progression of laryngeal and hypopharyngeal squamous cell carcinoma.
    Wang J; Lun L; Jiang X; Wang Y; Li X; Du G; Wang J
    Int Immunopharmacol; 2021 Aug; 97():107675. PubMed ID: 33964809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.
    Kursunel MA; Taskiran EZ; Tavukcuoglu E; Yanik H; Demirag F; Karaosmanoglu B; Ozbay FG; Uner A; Esendagli D; Kizilgoz D; Yilmaz U; Esendagli G
    Cancer Immunol Immunother; 2022 Feb; 71(2):445-459. PubMed ID: 34228218
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL20RA signaling enhances stemness and promotes the formation of an immunosuppressive microenvironment in breast cancer.
    Gao W; Wen H; Liang L; Dong X; Du R; Zhou W; Zhang X; Zhang C; Xiang R; Li N
    Theranostics; 2021; 11(6):2564-2580. PubMed ID: 33456560
    [No Abstract]   [Full Text] [Related]  

  • 34. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemerin Reactivates PTEN and Suppresses PD-L1 in Tumor Cells via Modulation of a Novel CMKLR1-mediated Signaling Cascade.
    Rennier K; Shin WJ; Krug E; Virdi G; Pachynski RK
    Clin Cancer Res; 2020 Sep; 26(18):5019-5035. PubMed ID: 32605911
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NANOGP8 is the key regulator of stemness, EMT, Wnt pathway, chemoresistance, and other malignant phenotypes in gastric cancer cells.
    Ma X; Wang B; Wang X; Luo Y; Fan W
    PLoS One; 2018; 13(4):e0192436. PubMed ID: 29689047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic stratification based on microenvironment immune types and PD-L1 for tailoring therapeutic strategies in bladder cancer.
    Lyu X; Wang P; Qiao Q; Jiang Y
    BMC Cancer; 2021 May; 21(1):646. PubMed ID: 34059019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Notum enhances gastric cancer stem-like cell properties through upregulation of Sox2 by PI3K/AKT signaling pathway.
    Liu Y; Chen H; Xiao L; Dong P; Ma Y; Zhou Y; Yang J; Bian B; Xie G; Chen L; Shen L
    Cell Oncol (Dordr); 2024 Apr; 47(2):463-480. PubMed ID: 37749430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumorigenic hybrids between mesenchymal stem cells and gastric cancer cells enhanced cancer proliferation, migration and stemness.
    Xue J; Zhu Y; Sun Z; Ji R; Zhang X; Xu W; Yuan X; Zhang B; Yan Y; Yin L; Xu H; Zhang L; Zhu W; Qian H
    BMC Cancer; 2015 Oct; 15():793. PubMed ID: 26498753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.